Eligard Related Published Studies
Well-designed clinical trials related to Eligard (Leuprolide)
The pharmacokinetics and pharmacodynamics of a new sustained-release leuprolide acetate depot compared to market references. [2008.08]
Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas. [2008.07]
Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas. [2007.11.12]
Impact of leuprolide acetate on luteal phase function in women undergoing controlled ovarian hyperstimulation and intrauterine insemination. [2006.02]
Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. [2006.02]
Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. [2006.01]
A randomized prospective study of microdose leuprolide versus ganirelix in in vitro fertilization cycles for poor responders. [2005.05]
Leuprolide acetate treatment with and without coadministration of tibolone in premenopausal women with menstrual cycle-related irritable bowel syndrome. [2005.04]
Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. [2004.11]
Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. [2004.07.01]
Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study. [2004]
Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. [2003.08]
Comparison of leuprolide acetate and triptorelin in assisted reproductive technology cycles: a prospective, randomized study. [2002.12]
The effects of gender and gonadal steroids on the neuroendocrine and temperature response to m-chlorophenylpiperazine in leuprolide-induced hypogonadism in women and men. [2002.11]
Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. [2002.09]
Comparison between a single dose of goserelin (depot) and multiple daily doses of leuprolide acetate for pituitary suppression in IVF treatment: a clinical endocrinological study of the ovarian response. [2002.07]
A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. [2002.04]
Prospective randomized comparison of ovarian blockade with nafarelin versus leuprolide during ovarian stimulation with recombinant FSH in an ICSI program. [2001.11]
A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. [2001.11]
Pulsatile iv infusion of recombinant human LH in leuprolide-suppressed men unmasks impoverished Leydig-cell secretory responsiveness to midphysiological LH drive in the aging male. [2001.11]
Randomized double-blind study evaluating the efficacy on uterine fibroids shrinkage and on intra-operative blood loss of different length of leuprolide acetate depot treatment before myomectomy. [2001.10]
Efficacy of ipriflavone in preventing adverse effects of leuprolide. [2001.07]
Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. [2001.02]
Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. [2001.01]
Do heavier women benefit from a higher dose of leuprolide acetate for suppression of serum estradiol? [2000.11]
Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. [2000.09]
Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients. [2000.08]
A randomized comparison of danazol and leuprolide acetate suppression of serum-soluble CD23 levels in endometriosis. [2000.06]
Delayed oral estradiol combined with leuprolide increases endometriosis-related pain. [2000.04]
Impact of nafarelin and leuprolide for endometriosis on quality of life and subjective clinical measures. [1999.12]
Use of vitamin K2 (menatetrenone) and 1,25-dihydroxyvitamin D3 in the prevention of bone loss induced by leuprolide. [1999.08]
Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group. [1999.01]
Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients. [1999]
[Clinical use of leuprolide acetate depot in a group of gynecologic patients in the preoperative period] [1998.11]
Comparison of goserelin and leuprolide in combined androgen blockade therapy. [1998.07]
Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease: a double-blind, placebo-controlled, randomized study. [1998.06]
A prospective randomized study to evaluate leuprolide acetate treatment before laparoscopic myomectomy: efficacy and ultrasonographic predictors. [1998.01]
Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. [1998.01]
Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group. [1997.07]
Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: a pilot study. [1996.12]
A double-blind comparison of nafarelin and leuprolide acetate for down-regulation in IVF cycles. [1996.09]
Acute hormonal responses to the gonadotropin releasing hormone agonist leuprolide: dose-response studies and comparison to nafarelin--a clinical research center study. [1996.09]
Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia. [1996.07]
A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin-releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. [1996.05]
Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study. [1995.12]
Subcutaneous low dose leuprolide acetate depot versus leuprolide acetate for women undergoing ovarian stimulation for in-vitro fertilization. [1995.11]
Leuprolide acetate treatment and myoma arterial size. [1995.09]
Sustained benefits of leuprolide acetate with or without subsequent medroxyprogesterone acetate in the nonsurgical management of leiomyomata uteri. [1995.08]
GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide Acetate Study Group. [1995.07]
Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. [1995.07]
Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. [1995.06]
Serum-soluble CD23 in patients with endometriosis and the effect of treatment with danazol and leuprolide acetate depot injection. [1995.04]
Profound luteinizing hormone suppression after stopping the gonadotropin-releasing hormone-agonist leuprolide acetate. [1995.03]
Effects of two different doses of leuprolide acetate depot on uterine cavity area in patients with uterine leiomyomata. [1995.03]
Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. [1994.11]
Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years. [1994.09]
Safety, side effects and patient acceptance of the luteinizing hormone releasing hormone agonist leuprolide in treatment of benign prostatic hyperplasia. [1994.08]
The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. [1994.06]
Effect of leuprolide acetate in patients with functional bowel disease. Long-term follow-up after double-blind, placebo-controlled study. [1994.06]
[Short-term treatment with leuprolide acetate depot before surgical intervention for uterine leiomyomatosis] [1994.06]
Comparison of leuprolide acetate and human chorionic gonadotropin for the induction of ovulation in clomiphene citrate-stimulated cycles. [1994.05]
Comparison between nafarelin and leuprolide acetate for in vitro fertilization: preliminary clinical study. [1994.04]
[Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol] [1994.04]
Leuprolide acetate depot decreases the number of nucleolar organizer regions in uterine leiomyomata. [1993.09]
Hypothalamic modulation of nociception and reproduction in cluster headache. I. Therapeutic trials of leuprolide. [1993.08]
A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. [1993.08]
Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. [1993.07]
The prognostic value of serum concentrations of progesterone, estradiol, and luteinizing hormone during superovulation with and without adjunctive leuprolide therapy. [1993.06]
Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results. [1992.11]
Randomized, prospective comparison of luteal leuprolide acetate and gonadotropins versus clomiphene citrate and gonadotropins in 408 first cycles of in vitro fertilization. [1992.09]
Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women. [1992.07]
Recurrence of myomas after myomectomy in women pretreated with leuprolide acetate depot or placebo. [1992.07]
Nafarelin versus leuprolide in ovulation induction for in vitro fertilization: a randomized clinical trial. [1992.05]
Leuprolide acetate-prepared in vitro fertilization-gamete intrafallopian transfer cycles: efficacy versus controls and cost analysis. [1992.03]
Adjunctive leuprolide therapy does not improve cycle fecundity in controlled ovarian hyperstimulation and intrauterine insemination of subfertile women. [1991.08]
The Lupron screening test: tailoring the use of leuprolide acetate in ovarian stimulation for in vitro fertilization. [1991.07]
A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas. [1991.06]
Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. [1991.05]
Treatment of newly diagnosed state D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036. [1990.12.20]
Randomized, prospective trial of leuprolide acetate and conventional superovulation in first cycles of in vitro fertilization and gamete intrafallopian transfer. [1990.11]
Leuprolide with and without flutamide in advanced prostate cancer. [1990.09.01]
Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. [1990.09]
Evaluation of leuprolide acetate and gonadotropins versus clomiphene citrate and gonadotropins for in vitro fertilization or gamete intrafallopian transfer. [1990.07]
The luteal phase in polycystic ovary syndrome during ovulation induction with human menopausal gonadotropin with and without leuprolide acetate. [1990.07]
Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate. [1990.06]
Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism. [1990.04]
Fasting serum growth hormone and insulin-like growth factor-I and -II concentrations in women with leiomyomata uteri treated with leuprolide acetate or placebo. [1990.02]
Clinical characteristics of ovulation induction with human menopausal gonadotropins with and without leuprolide acetate in polycystic ovary syndrome. [1989.12]
A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata. [1989.12]
A randomized, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy. [1989.11]
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. [1989.08.17]
A randomized, prospective comparison of endocrine changes induced with intranasal leuprolide or danazol for treatment of endometriosis. [1989.03]
A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata. [1989.02]
A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. [1988.03]
Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist. [1987.10]
Well-designed clinical trials possibly related to Eligard (Leuprolide)
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. [2008.10]
A randomised controlled trial comparing GnRH antagonist cetrorelix with GnRH agonist leuprorelin for endometrial thinning prior to transcervical resection of endometrium. [2008.09]
Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. [2008.06.20]
Effect of ovarian suppression with gonadotropin-releasing hormone agonist on glucose disposal and insulin secretion. [2008.06]
Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle-stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients. [2008.04]
Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization. [2008.03]
|
